Abi Pesun, director at Almac ONE explains how a shift towards unified supply chain management can accelerate timelines and help mitigate risk for clinical trials during Covid-19.
Time management
In light of the global pandemic, sponsors are having to strategically re-evaluate their R&D pipelines and decide whether or not planned clinical trials can go ahead in existing timeframes and if existing trials can continue in their current scope of work, due to in-country restrictions globally. For sponsors conducting Covid-19 studies, they need to decide whether to re-prioritise over existing studies and if so, they have to set up with accelerated timelines, due to the urgent need to establish drug efficacy in prevention or treatment of the virus.
With so much new and additional disruption and complexity to navigate, designing and maintaining streamlined clinical supply chains that safeguard timely, compliant and cost-effective drug production and distribution to patients matters more than ever.